BiotechTube

Temozolomide

Phase 1Terminated
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma

Conditions

Glioma

Trial Timeline

Apr 17, 2017 → Jul 27, 2020

NCT ID
NCT02507232

About Temozolomide

Temozolomide is a phase 1 stage product being developed by Novocure for Glioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02507232. Target conditions include Glioma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (6)

NCT IDPhaseStatus
NCT03705351Phase 1Terminated
NCT03477110Phase 1Completed
NCT03232424Phase 1Completed
NCT03780569Pre-clinicalUNKNOWN
NCT02507232Phase 1Terminated
NCT00916409Phase 3Completed

Competing Products

20 competing products in Glioma

See all competitors
ProductCompanyStageHype Score
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
LY2157299 + LomustineEli LillyPhase 1
33
DS-1001bDaiichi SankyoPhase 2
52
DS-1001bDaiichi SankyoPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Temozolomide and BevacizumabEisaiPhase 2
52
TemozolomideEisaiPhase 2
52
Gliadel Wafer + TemozolomideEisaiPhase 2
52
Palonosetron (PALO)EisaiPhase 2
52
Gliadel/Avastin/CPT-11EisaiPhase 2
52
Lenvatinib + BevacizumabEisaiPhase 2
52
Granisetron + OndansetronKyowa KirinPhase 2
52
Binimetinib 15 MGOno PharmaceuticalPhase 2
52
EnzastaurinEli LillyPhase 2
52
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
33
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
41
Abemaciclib + TemozolomideEli LillyPhase 2
52
DSP-0390Sumitomo PharmaPhase 1
33
DSP-0390Sumitomo PharmaPhase 1
33
ApatinibJiangsu Hengrui MedicinePhase 2
52

Other Products from Novocure

PaclitaxelPhase 3
72
Pembrolizumab + Platinum based chemotherapyPhase 3
72
Gemcitabine + nab paclitaxelPhase 3
72
TemozolomidePhase 3
72
Immune checkpoint inhibitors or docetaxelPhase 3
72